• Something wrong with this record ?

Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells

J. Tenhunen, T. Kučera, M. Huovinen, J. Küblbeck, E. Bisenieks, B. Vigante, Z. Ogle, G. Duburs, M. Doležal, R. Moaddel, M. Lahtela-Kakkonen, M. Rahnasto-Rilla

. 2021 ; 138 (-) : 111452. [pub] 20210305

Language English Country France

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21025637

Sirtuin 6 (SIRT6), a member of sirtuin family (SIRT1-7), regulates a variety of cellular processes involved in aging, metabolism, and cancer. Dysregulation of SIRT6 is widely observed in different breast cancer subtypes; however, the role and function of SIRT6 in cancer development remain largely unexplored. The aim of this study was to identify novel compounds targeting SIRT6 which may provide a new approach in development of anti-cancer therapy for breast cancer. Virtual screening was utilized to discover potential compounds targeting SIRT6 for in vitro screening. In addition, novel 1,4-dihydropyridine derivatives were synthetized and further subjected for the screening. The impact of the compounds on the deacetylation activity of SIRT6 was determined with HPLC method. The anti-cancer activities were screened for a panel of breast cancer cells. A set of 1,4-dihydropyridine derivatives was identified as SIRT6 inhibitors. A SIRT6 activating compound, (2,4-dihydroxy-phenyl)-2-oxoethyl 2-(3-methyl-4-oxo-2-phenyl-4H-chromen-8-yl)acetate (later called as 4H-chromen), was discovered and it provided 30-40-fold maximal activation. 4H-chromen was proposed to bind similarly to quercetin and place to previously reported SIRT6 activator sites. 4H-chromen was investigated in various breast cancer cells, and it decreased cell proliferation in all cells as well as arrested cell cycle in triple negative cells. Overall, this study describes a highly potent SIRT6 activator and new inhibitors that represent a novel tool to study the mechanism of SIRT6 function.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025637
003      
CZ-PrNML
005      
20240522135514.0
007      
ta
008      
211013e20210305fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2021.111452 $2 doi
035    __
$a (PubMed)33684691
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Tenhunen, Jonna $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland
245    10
$a Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells / $c J. Tenhunen, T. Kučera, M. Huovinen, J. Küblbeck, E. Bisenieks, B. Vigante, Z. Ogle, G. Duburs, M. Doležal, R. Moaddel, M. Lahtela-Kakkonen, M. Rahnasto-Rilla
520    9_
$a Sirtuin 6 (SIRT6), a member of sirtuin family (SIRT1-7), regulates a variety of cellular processes involved in aging, metabolism, and cancer. Dysregulation of SIRT6 is widely observed in different breast cancer subtypes; however, the role and function of SIRT6 in cancer development remain largely unexplored. The aim of this study was to identify novel compounds targeting SIRT6 which may provide a new approach in development of anti-cancer therapy for breast cancer. Virtual screening was utilized to discover potential compounds targeting SIRT6 for in vitro screening. In addition, novel 1,4-dihydropyridine derivatives were synthetized and further subjected for the screening. The impact of the compounds on the deacetylation activity of SIRT6 was determined with HPLC method. The anti-cancer activities were screened for a panel of breast cancer cells. A set of 1,4-dihydropyridine derivatives was identified as SIRT6 inhibitors. A SIRT6 activating compound, (2,4-dihydroxy-phenyl)-2-oxoethyl 2-(3-methyl-4-oxo-2-phenyl-4H-chromen-8-yl)acetate (later called as 4H-chromen), was discovered and it provided 30-40-fold maximal activation. 4H-chromen was proposed to bind similarly to quercetin and place to previously reported SIRT6 activator sites. 4H-chromen was investigated in various breast cancer cells, and it decreased cell proliferation in all cells as well as arrested cell cycle in triple negative cells. Overall, this study describes a highly potent SIRT6 activator and new inhibitors that represent a novel tool to study the mechanism of SIRT6 function.
650    _2
$a protinádorové látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $7 D001943
650    _2
$a viabilita buněk $x účinky léků $x fyziologie $7 D002470
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $x metody $7 D004354
650    _2
$a časná detekce nádoru $x metody $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a simulace molekulového dockingu $x metody $7 D062105
650    _2
$a sekundární struktura proteinů $7 D017433
650    _2
$a terciární struktura proteinů $7 D017434
650    _2
$a sirtuiny $x antagonisté a inhibitory $x chemie $x metabolismus $7 D037761
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kučera, Tomáš $u Faculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic
700    1_
$a Huovinen, Marjo $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland
700    1_
$a Küblbeck, Jenni $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland
700    1_
$a Bisenieks, Egils $u Latvian Institute of Organic Synthesis, Riga, Latvia
700    1_
$a Vigante, Brigita $u Latvian Institute of Organic Synthesis, Riga, Latvia
700    1_
$a Ogle, Zaiga $u Latvian Institute of Organic Synthesis, Riga, Latvia
700    1_
$a Duburs, Gunars $u Latvian Institute of Organic Synthesis, Riga, Latvia
700    1_
$a Doležal, Martin, $d 1961- $u Faculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic $7 jn19981000714
700    1_
$a Moaddel, Ruin $u Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD, United States
700    1_
$a Lahtela-Kakkonen, Maija $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Electronic address: maija.lahtela-kakkonen@uef.fi
700    1_
$a Rahnasto-Rilla, Minna $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Electronic address: minna.rahnasto@uef.fi
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 138 (20210305), s. 111452
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33684691 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240522135510 $b ABA008
999    __
$a ok $b bmc $g 1714609 $s 1146144
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 138 $c - $d 111452 $e 20210305 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options